Astrazeneca ADR Stock
Your prediction
Astrazeneca ADR Stock
So far the community has only identified positive things for Astrazeneca ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | - | - | - | - | - | - | - |
| Bayer AG ADR | -3.720% | -0.529% | -2.083% | 57.983% | 6.818% | -34.266% | -28.244% |
| Novartis AG ADR | 1.610% | 0.000% | -7.463% | 22.167% | 4.641% | 30.526% | 73.669% |
| UCB S.A. | 1.360% | -4.238% | -13.919% | 34.473% | -3.875% | 178.564% | 198.145% |
News
P&G and OMP Showcase the Path to Autonomous, Decision-Centric Planning at Gartner Supply Chain Symposium/Xpo 2026
How decision velocity is closing the gap between insight and action across one of the world's most complex value chains
ATLANTA, GA / ACCESS Newswire / April 14, 2026 / OMP, a leader in
As Investors Flee U.S. Equities, This Global ETF Is Outperforming
Since the start of the year, investors have been vacating U.S. stocks and exchange-traded funds (ETFs) in a broad-based, risk-off strategy that has benefited safe-haven assets like gold and silver
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound
Since going public in mid-2024, shares of healthcare and life science services company Tempus AI (NASDAQ: TEM) have gone on a wild rollercoaster ride. The firm’s initial public offering price